about
EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcriptionLigand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonistPriming of protective T cell responses against virus-induced tumors in mice with human immune system componentsEpstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developmentsLymphoma Immunotherapy: Current StatusEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderEpstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantNK Cell Influence on the Outcome of Primary Epstein-Barr Virus InfectionResveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cellsMHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.Epstein-Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signalImmunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapyRole of the ubiquitin system and tumor viruses in AIDS-related cancer.Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1.Dendritic cells during Epstein Barr virus infection.Viral latency and its regulation: lessons from the gamma-herpesviruses.Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression.Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted functionTowards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH.Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.Cytolytic T lymphocytes from HLA-B8+ donors frequently recognize the Hodgkin's lymphoma associated latent membrane protein 2 of Epstein Barr virus.Mice with human immune system components as in vivo models for infections with human pathogens.Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Cytotoxic T lymphocytes as immune-therapy in haematological practice.Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens.Host genetics of Epstein-Barr virus infection, latency and disease.A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cellsEBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetilSuccessful Treatment of Posttransplant EBV-Associated Lymphoma and Plasmacytoma Solely Localized to the CNSDonor CD4 T Cell Diversity Determines Virus Reactivation in Patients After HLA-Matched Allogeneic Stem Cell TransplantationPreemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines.
P2860
Q24298061-32DDB317-FA2E-4980-999E-93864B1E5754Q24306565-6370EC30-D0EC-4DAC-9EFC-0D69126716BEQ24645297-3B3E418E-66A8-4BD4-9673-D26F74510ECBQ26775442-DA3C421A-6134-462B-9475-1C9D78D0828BQ26782902-0E128879-1B82-48D5-8F7B-074CAEDDA627Q26859114-0E70B37A-74D2-40DD-AFAD-EEA0633A1C24Q26861623-6E4A7256-69E4-4ADF-A4CE-613C3926009DQ28069456-6C7F652E-0D5A-4B8C-BD4D-262E0B5433CBQ28484266-71659A12-EBEA-4DED-BD09-B1BC7D7CD02CQ30412320-372748BE-F11D-4E12-88C0-1AFB4AD6FCE8Q30514070-FDD36089-095C-48EC-8501-A81C10081BE1Q33289956-E7A013D0-EAB6-4DC0-AA9F-A57EE61C86C6Q33307881-1BA37D04-87EA-46D7-922C-20A961E4F09EQ33712662-E76431EB-7908-42C3-94EE-2944983E9E06Q33782152-0B590F09-237D-49AF-9C1D-159F6D62D42DQ34039189-4BEFC23A-BBB0-4C8B-8D56-8A2561D6D695Q34042343-CA679655-2749-4B6D-9D81-D97D7E79E00BQ34061575-86561932-EE69-4BA5-88D8-ECD10A3B1693Q34186560-0C759437-6207-4679-A148-44E8BBB46951Q34353696-A2395AB9-2A84-4E06-B001-6AC5E807785DQ34374063-CE107CE8-5113-4D22-A9A5-5A34820E9A63Q34374436-CFB0A83E-5A88-430B-9AC0-F9CEBD940738Q34712758-F51DB84E-D503-4275-A9F9-C2C37031FA10Q34920166-AE46676A-3D11-4F1E-849C-9CC6401926FDQ34985738-1567E743-DF79-407D-9F5F-3B020E5748A3Q35083003-33F782D6-C373-44D4-99C3-E3C16CA88344Q35157540-4A10482E-590A-4414-8133-FD1E0671C243Q35177618-1D426F13-3A75-47A6-A68A-243B851B2325Q35423739-70577AE7-5259-4D93-A6BF-FCF39D1E5E4DQ35479272-899D9386-7040-4D03-913A-F28521DFA8F2Q35532450-821B15B4-3807-4DA1-B903-0A0D29DF0213Q35639567-8F2B5DCD-A61D-4A4B-B642-DF0E153B0BDCQ35849039-365422A7-A287-443A-9C04-6D641032047DQ35857336-0AD1A23B-8C46-46AD-87BF-3877EDB8A4C8Q35858022-1A776DA9-1D59-4873-A919-7B7B3F2E89DAQ35870511-9784CE45-FC06-4D0C-A5DC-7DE2A065DDDEQ36169107-711F9F04-1DE4-46BB-A05C-00D4F58A8E88Q36302494-3ADB7B35-9C0F-47C5-86EA-C89245D297A7Q36389306-6EDA2A5C-DE91-4209-8CB4-0FAC3554B2CDQ36407109-F2C2415C-E1F7-4FAC-ADF5-4629A236A375
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Post-transplant lymphoproliferative disorders.
@ast
Post-transplant lymphoproliferative disorders.
@en
Post-transplant lymphoproliferative disorders.
@nl
type
label
Post-transplant lymphoproliferative disorders.
@ast
Post-transplant lymphoproliferative disorders.
@en
Post-transplant lymphoproliferative disorders.
@nl
prefLabel
Post-transplant lymphoproliferative disorders.
@ast
Post-transplant lymphoproliferative disorders.
@en
Post-transplant lymphoproliferative disorders.
@nl
P2093
P1476
Post-transplant lymphoproliferative disorders.
@en
P2093
Cliona M Rooney
Helen E Heslop
Stephen Gottschalk
P356
10.1146/ANNUREV.MED.56.082103.104727
P577
2005-01-01T00:00:00Z